Metelimumab

Metelimumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetTGF beta 1
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma.[1] It was dropped from further development in favour of fresolimumab,[2] which was being developed by Genzyme as of 2006.[3]

History

Metelimumab was isolated by Cambridge Antibody Technology (CAT) using its phage display technology. In 2000, CAT signed a collaborative deal with Genzyme to further develop TGF beta antibodies.[4][5]

In 2004, CAT and Genzyme revealed that Phase I/II trials of metelimumab for scleroderma showed this antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.[6]

Initial trials targeted the skin condition scleroderma[7] but, after some unsuccessful clinical trial results, the product was dropped in favour of fresolimumab,[2] which was being developed by Genzyme as of 2006.[3]

References

  1. ↑ Sorbera LA (2004). "Metelimumab: Agent for scleroderma prop inn human anti-TGF-β1 monoclonal antibody". Drugs of the Future. 29 (11): 1081–3. doi:10.1358/dof.2004.029.11.860002.
  2. 1 2 Foley S (10 February 2004). "CAT may abandon skin drug after trial results disappoint". {{cite journal}}: Cite journal requires |journal= (help)
  3. 1 2 "Tasidotin". Genzyme. 2006. Archived from the original on 2006-09-02. Retrieved 2009-07-27.
  4. ↑ "Genzyme General and Cambridge Antibody Technology To Collaborate on Development of Human Anti-TGF-beta Monoclonal Antibodies". PR News Wire. Archived from the original on 15 July 2011.
  5. ↑ "Cambridge Antibody, Genzyme to collaborate on human anti-TGFBeta monoclonals". Drug Discovery Online. 2 October 2000.
  6. ↑ "CAT-192 is safe but efficacy in doubt". The Pharma Letter. 16 February 2002.
  7. ↑ Clinical trial number NCT00043706 for "Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis" at ClinicalTrials.gov


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.